PON1 and acute coronary syndrome: Conversely, in patients with acute coronary syndrome, the polymorphism Q192R of paraoxonase-1 enzyme (PON1), which codes for a high-density lipoprotein-associated antioxidant enzyme (containing ARE/Nrf2 binding sites in its promoter), did not hamper the biotransformation of clopidogrel, unaltering its potential efficacy to treat cardiovascular events [129].